Awareness and Equity in OC

CE / CME

Improving Provider Awareness About Healthcare Equity: Improving All Patients’ Access to Care in Ovarian Cancer

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: April 25, 2023

Expiration: April 24, 2024

Shannon N. Westin
Shannon N. Westin, MD, MPH, FASCO

Activity

Progress
1
Course Completed

References

  1. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: ovarian cancer. seer.cancer.gov/statfacts/html/ovary.html. Accessed March 9, 2023.
  2. Ovarian Cancer Research Alliance. Recurrence. ocrahope.org/patients/diagnosis-and-treatment/recurrence. Accessed March 9, 2023.
  3. Hanker LC, Loibl S, Burchardi N, et al; AGO and GINECO study group. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23:2605-2612.
  4. Morris CR, Sands MT, Smith LH. Ovarian cancer: predictors of early-stage diagnosis. Cancer Causes Control. 2010;21:1203-1211. 
  5. Graham S, Hallisey E, Wilt G, et al. Sociodemographic disparities in access to ovarian cancer treatment. Ann Cancer Epidemiol. 2019;3:10.21037/ace.2019.10.02.
  6. Taylor JS, He W, Harrison R, et al. Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol. 2018;151:269-274.
  7. Kaufman M, Cruz A, Thompson J, et al. A review of the effects of healthcare disparities on the experience and survival of ovarian cancer patients of different racial and ethnic backgrounds. J Cancer Metastasis Treat. 2019;5:13.
  8. Huang M, Kamath P, Schlumbrecht M, et al. Identifying disparities in germline and somatic testing for ovarian cancer. Gynecol Oncol. 2019;153:297-303.
  9. Park HK, Ruterbusch JJ, Cote ML. Recent trends in ovarian cancer incidence and relative survival in the United States by race/ethnicity and histologic subtypes. Cancer Epidemiol Biomarkers Prev. 2017;26:1511-1518.
  10. Bristow RE, Chang J, Ziogas A, et al. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol. 2014;132:403-410.
  11. Long B, Chang J, Ziogas A, et al. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol. 2015;212:468.e1-9.
  12. Chatterjee S, Gupta D, Caputo TA, et al. Disparities in gynecological malignancies. Front Oncol. 2016;6:36.
  13. Bandera EV, Lee VS, Rodriguez-Rodriguez L, et al. Racial/ethnic disparities in ovarian cancer treatment and survival. Clin Cancer Res. 2016;22:5909-5914.
  14. Patel KB, Pyrzak A, Williams H, et al. Participation in clinical trials may overcome health disparities in the treatment of advanced or recurrent epithelial ovarian cancer. Presented at: 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 24-27, 2018. Abstract 6.
  15. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: ovarian cancer. v.1.2023. nccn.org. Accessed March 9, 2023.
  16. Society of Gynecologic Oncology. Clinical practice guidelines: genetic testing for ovarian cancer. Society of Gynecologic Oncology; 2014. 
  17. American Society of Clinical Oncology. Genetics toolkit. American Society of Clinical Oncology; 2021. 
  18. European Society for Medical Oncology. Newly diagnosed and relapsed epithelial ovarian carcinoma treatment recommendations. European Society for Medical Oncology; 2020.
  19. Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38:1222-1245.
  20. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5:1137-1154.
  21. Kurian AW, Ward KC, Howlader N, et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019;37:1305-1315.
  22. Niraparib [prescribing information]. Durham, NC: GlaxoSmithKline; 2022.
  23. Olaparib [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022.
  24. Rucaparib [prescribing information]. Boulder, CO: Clovis Oncology, Inc; 2022.
  25. González-Martín A, Pothuri B, Vergote I, et al; PRIMA/ENGOT-OV26/GOG-3012 investigators. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391-2402.
  26. Li N, Zhu J, Yin R, et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME study): a randomized, double-blind, placebo- controlled, phase 3 trial. Presented at: 2022 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 18-21, 2022. Abstract 244. 
  27. Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22:1721-1731.
  28. Monk BJ, Parkinson C, Lim MC, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022;40:3952-3964. 
  29. Ray-Coquard I, Pautier P, Pignata S, et al; PAOLA-1 investigators. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416-2428.
  30. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495-2505.
  31. Bradley W, Moore K, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO-1. Presented at: Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 19-25, 2021. Abstract 38.
  32. LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20:e15-e28.
  33. Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32:757-765.
  34. Matulonis U, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. Presented at: 2022 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 18-21, 2022. Abstract 242.
  35. Scalici J, Finan MA, Black J, et al. Minority participation in Gynecologic Oncology Group (GOG) studies. Gynecol Oncol. 2015;138:441-444.
  36. Patel SN, Staples JN, Garcia C, et al. Are ethnic and racial minority women less likely to participate in clinical trials? Gynecol Oncol. 2020;157:323-328.
  37. Igwe E, Woodburn J, Davolos J, et al. Patient perceptions and willingness to participate in clinical trials. Gynecol Oncol. 2016;142:520-524.
  38. Esnaola NF. A blueprint for addressing cancer disparities. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021.
  39. Oskay-Özcelik G, Alavi S, Richter R, et al. Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. Ann Oncol. 2018;29:910-916.
  40. Nyakudarika NC, Holschneider CH, Sinno AK. Universal social needs assessment in gynecologic oncology: An important step toward more informed and targeted care in the public safety net. Cancer. 2021;127:3809-3816.
  41. Durant RW, Wenzel JA, Scarinci IC, et al. Perspectives on barriers and facilitators to minority recruitment for clinical trials among cancer center leaders, investigators, research staff, and referring clinicians: enhancing minority participation in clinical trials (EMPaCT). Cancer. 2014;120(suppl 7):1097-1105.
  42. Pozzar RA, Berry DL. Patient-centered research priorities in ovarian cancer: a systematic review of potential determinants of guideline care. Gynecol Oncol. 2017;147:714-722.
  43. Binner M, Figlioli A, Shanahan J, et al. Oncology nurse navigator’s rapid improvement event: improving processes and identifying metrics. J Onc Nav Surviv. 2019;10.